Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Lytix Biopharma AS ( (DE:6BG) ).
Lytix Biopharma has announced that the USPTO has issued a Notice of Allowance for their U.S. patent application regarding the use of LTX-315 with PD-1 immune checkpoint inhibitors. This development strengthens Lytix Biopharma’s intellectual property portfolio, enhancing their competitive position in the U.S. pharmaceutical market and supporting the long-term value of their clinical programs. Currently, LTX-315 is under evaluation in two Phase II clinical trials, which could further solidify Lytix’s role in cancer immunotherapy.
More about Lytix Biopharma AS
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company specializing in innovative cancer treatments. With a focus on host-defense peptide-derived molecules, their lead product, LTX-315, is a first-in-class oncolytic molecule designed to enhance anti-cancer immunity. Their pipeline includes molecules applicable to various cancer indications and treatment settings, both as mono- and combination therapies.
YTD Price Performance: -2.08%
Average Trading Volume: 2,166
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €33.76M
For detailed information about 6BG stock, go to TipRanks’ Stock Analysis page.